麥迪衞康(02159.HK)2023年度收入增加約2.5%至約3.31億元
格隆匯3月27日丨麥迪衞康(02159.HK)發佈公吿,集團的收入由截至2022年12月31日止年度的約人民幣323.4百萬元增加約2.5%至2023年度的約人民幣331.3百萬元。集團本年度錄得年內虧損約人民幣96.1百萬元,而截至2022年12月31日止年度為年內虧損約人民幣93.7百萬元,原因為以下的合併影響所致:(i)本年度毛利下跌,主要由於本年度利潤率較低的營銷戰略和諮詢服務收入佔比提升;(ii)本年度為客觀公平反映集團財務狀況及資產價值而計提無形資產減值;及(iii)集團於本年度進行研發項目,包括數字醫療解決方案,人工智能機械人及網上平台相關研發開支減少。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.